Rejuvenate Biomed closes in on €9 million funding round for human trials of sarcopenia-targeted combined drug.
Already well-known for its beer and bureaucracy to its...
Dr Oliver Zolman makes the case for Longevity companies adopting a checklist when it comes to making anti-aging claims.
When it comes to marketing in...
Phase 2-ready drug can treat and reverse immune aging, BioAge claims.
BioAge Labs' in-licensed clinical-stage therapy has potential for treating immune aging in older patients...
Leading academic says high profile trial failures should drive changes in how we approach trials for drugs that target aging.
Following the recent clinical trial...
Buck professor Brian Kennedy talks about AKG and the potential for supplements to deliver real anti-aging benefits.
Following Tuesday’s news from the Buck Institute about...
The Buck's new peer-reviewed study of alpha-ketoglutarate shows a significant reduction in frailty in older mice, resulting in compression of late-life morbidity.
The Buck Institute...
As Healthy Aging Month arrives, Dr Thomas Rando shares his views on progress in Longevity science.
For the past two decades, September has been celebrated...
Company to focus on ophthalmologic and neurologic programs as Phase 2 knee osteoarthritis clinical study fails to meet primary endpoint.
Senolytic therapy developer UNITY...
A new survey on translational processes and hurdles to clinical trials in Longevity biotech.
We're working with two MDs: Oliver Zolman and Jian Fransen, on...
Alkahest pipeline sees multiple therapeutic candidates progressing through clinical trials.
Biopharmaceutical company Alkahest has released details of its progress on a range of therapeutic candidates;...
A new paper supports the targeting of aging processes, rather than just one disease, to improve Longevity outcomes.
Multimorbidity is a challenge for Longevity; defined...
Nuritas launches PeptiYouth™ an AI-discovered peptide, clinically proven, anti-aging molecule.
Nuritas, a leader in Artificial Intelligence-based peptide discovery, has launched PeptiYouth™, a peptide discovered within peas and which, following clinical trials, has been shown...
Insilico and Oxford University used machine learning to predict major clinical forms of drug cardiotoxicity.
Insilico Medicine announced this week that they, in partnership with...
Braincures raising funds to take-on AI drug discovery for Alzheimer’s and other neurological diseases with data analysis and systems biology.
The treatment of neurological diseases...
Longeveron announces Phase 2 clinical trial to evaluate the safety and efficacy of Mesenchymal Stem Cells (LMSCs) for the treatment of aging frailty in...
Extra-corporeal medical device could improve neuro outlook for end-stage renal disease patients.
Alkahest has announced its first foray into dialysis-associated dementia with a new randomised,...
Indian start-up Nugenics Research to commercialise “Elixir” after showing 54% age reversal in animal study.
The topic of using blood plasma to address human Longevity...
New breakthrough by a team led by eminent oncologist Loren Walensky brings new hope for future cancer treatments – and Longevity.
Everyone needs a way...
Quicksilver's liposomal delivery system boasts a non-invasion of the body patchers.
Colorado-based Quicksilver Scientific manufactures a range of supplements from immunity boosters to NAD+. By...
Master Investor is a publication that helps private investors to take charge of their financial destiny: covering a range of subjects, from shares to...
![Ozone therapy recently hit the headlines as one of the many treatment options being examined to mitigate the effects of COVID-19 [1], but it is also showing great promise in the treatment of neurodegenerative conditions such as Alzheimer’s and Parkinson's.](https://www.longevity.technology/wp-content/uploads/2020/10/Ozone-therapyW-218x150.jpg "Stopping neurodegeneration in its tracks with ozone therapy")
